Although inherited DNA sequences have a well-demonstrated role in psychiatric disease risk, for even the most heritable mental disorders, monozygotic twins are discordant at a significant rate. The genetic variation associated with mental disorders has heretofore been based on the search for rare or common variation in blood cells. This search is based on the premise that every somatic cell shares an identical DNA sequence, so that variation found in lymphocytes should reflect variation present in brain cells. Evidence from the study of cancer cells, stem cells and now neurons demonstrate that this premise is false. Somatic mutation is common in human cells and has been implicated in a range of diseases beyond cancer. The exuberant proliferation of cortical precursors during fetal development provides a likely environment for somatic mutation in neuronal and glial lineages. Studies of rare neurodevelopmental disorders, such as hemimegencephaly, demonstrate somatic mutations in affected cortical cells that cannot be detected in unaffected parts of the brain or in peripheral cells. This perspective argues for the need to investigate somatic variation in the brain as an explanation of the discordance in monozygotic twins, a proximate cause of mental disorders in individuals with inherited risk, and a potential guide to novel treatment targets. (2014) 19, 156-158; doi:10.1038/mp.2013.168; published online 17 December 2013
Now my own suspicion is that the Universe is not only queerer than we suppose, but queerer than we can suppose; 'JBS Haldane, Possible Worlds, 1927, p 286'.
What Haldane suggested of the universe certainly seems to be emerging as an undeniable fact about the brain. Looking at recent reports on transcription within the mammalian brain, the findings are indeed surprising beyond what we would have or could have suspected from studying other organs. Best estimates from the human brain suggest that 86% of the genome is expressed in the brain, with over 90% of these genes showing different patterns of expression prenatally 1, 2 (http://www.brainspan.org). Molecular phenomena, such as genomic imprinting, that are tightly controlled in peripheral organs appear to run rampant in the mouse brain with as many as 1000 genes showing mono-allelic expression. 3 Even the rules for epigenomics seem to be re-written in brain. Whereas methylation in most of the body occurs at cytosine-guanine dinucleotide sites, in the brain methylation is found mostly at dinucleotide sites of cytosine with adenine, thymine or cytosine. 4, 5 These remarkable and unexpected aspects of gene expression in the brain have emerged from studies of the transcriptome. What has been largely overlooked until recently has been the brain's genome. Why should we look at DNA sequence in the brain? After all, every cell is derived from a single progenitor, yielding each person's inherited genetic blueprint. Therefore, sequencing from a blood cell or buccal smear should yield a faithful representation of the DNA of every neuron and every other somatic cell. Except it does not. Recent sequencing of prefrontal cortical neurons suggest high variability, with 18 000 retrotransposons identified 6, 7 (although also see ref. 8) . That is, DNA from blood or buccal cells is not always identical with DNA in the brain and DNA sequence in one neuron may not be identical to a neighboring neuron or neighboring brain regions. These are somatic mutations as opposed to germline mutations that are inherited and found in every cell. Somatic mutations are believed to be the cause of most cancers. 9 A spontaneous mutation in a tumor suppressor or cell cycle driver gene alters the normal regulation of cell division leading to unregulated growth. These mutations are not only the proximate cause of cancer, they have become the preferred targets for drug development allowing oncology to move from broad cell cycle toxins to targeted therapies with much better outcomes. And they explain the limited heritability of several cancers. What may be inherited in the germline is not the specific causal mutation but the more general capacity for genomic surveillance that detects somatic changes or genomic stability that protects against such mutations. Importantly, the germline variant is the basis for heritable risk, whereas the causal gene is unique to the tumor.
How often does somatic variation occur outside of cancer cells? Changes in DNA sequence have been an important concern in stem cell biology as it has become evident that cells in culture are prone to de novo mutations as they divide. In an attempt to reduce this variation, Vaccarino and colleagues 10 studied the process by which fibroblasts undergoing de-differentiation to iPS cells developed these mutations. To their surprise, the sequence variation was present before the cells were manipulated. Indeed, mosaicism or DNA sequence variation within an individual is a well-known phenomenon ranging from duplication of a chromosome (aneuploidy) to single-base changes, associated with at least 30 Mendelian diseases. 11 Our singular focus on DNA from blood or buccal smears assumes that these cells are identical to all somatic cells, when, in fact, they may not even be similar to each other. Somatic mutations may seem unlikely for brain disorders because outside of the dentate gyrus of the hippocampus and the rostral migratory stream, nearly all forebrain neurons are postmitotic. Although most neurons in the adult do not divide, during the first half of human gestation the proliferation of cells may be higher than in any organ at any period of development. By week 24 of gestation, the human brain has generated 10 10 neurons from a few progenitors at week 4 (www.translatingtime.org). Even by a conservative estimate, proliferation during this 20-week interval (roughly 10 5 min) clocks out at over 10 5 divisions per minute, faster than any cancer or other somatic cell. If one were looking for an organ and a time with the highest risk for somatic mutations, early brain development fits the bill. Indeed, given the high rate of mutation, it seems implausible that somatic mutations are not abundant in the human brain.
There are, in fact, several brain diseases due to mutations that would be lethal in the zygote but are tolerated when they emerge later in development as somatic mutations. The disease is not inherited in the classic sense, as the mutation is embryonic lethal. But emergence later in development is compatible with survival although it is not likely to be transmitted, and therefore is under powerful negative selection. Poduri and colleagues 12 recently reviewed several examples of somatic mutations detected in brain as well as multiple peripheral tissues. These are generally rare neurodevelopmental syndromes that are not inherited in a classic sense.
Are there functional somatic mutations found only in the human brain? A recent paper demonstrated AKT3 mutations in brain tissue from children with hemimegalencephaly, a developmental brain disorder characterized by an enlarged, malformed cerebral hemisphere, intractable epilepsy and intellectual deficits. 13 These mutations were found in brain tissue resected surgically from hemimegalencephaly patients but, in some cases, not in their blood cells and, importantly, not in cells from the unaffected part of the brain. Surprisingly, the mutation was found in as few as 8% and generally o 35% of cells (both neurons and glia) in the affected tissue. The presence in both neurons and glia demonstrate that this mutation occurred in a common progenitor. The low fraction of affected cells reminds us that somatic mutations in such a clone can still be enough to disturb cortical architecture.
Could forebrain somatic mutations be a factor in mental illness? Somatic mutations would be consistent with the discordance found in monozygotic twins in every psychiatric disorder, the higher prevalence in males for most neurodevelopmental disorders (X-linked mutations would be more penetrant in males), and the high rates of de novo events in neurodevelopmental disorders suggesting a predisposition to somatic mutations. Although the data for schizophrenia remain inconclusive, children with autism and intellectual disability are clearly more likely to have de novo mutations, either as single-base changes or as larger structural variants.
14 These de novo mutations in affected children are presumably due to transmission from an affected sperm or egg but not present in the blood of either parent. Such de novo events would be transmitted to every cell in the child. They are thus different from somatic mutations that occur during mitosis following fertilization and formation of the zygote and result in mosaicism in the developing fetus. These de novo mutations may still be important clues for brain somatic changes. Neurofibromatosis and tuberous sclerosis are examples of 'two hit' syndromes in which a mutation on one allele is inherited and the second allele is altered only in the affected tissue. [15] [16] [17] Although we have long known about brain mosaicism from mitochondrial DNA mutations, 18 there are only limited data to support the hypothesis that somatic mutations within genomic DNA are involved in psychiatric disorders, mostly from case studies of aneuploidy. 19, 20 We have postmortem studies of transcriptional profiles but there are few studies that have looked for DNA sequence differences in identified cell lineages selected in psychiatric populations. 21 The key to finding a difference is knowing where to look. A cubic mm of neocortex homogenized for DNA will contain nearly 100 000 neurons of many different types along with an equal number of glia and additional vascular cells. In such a heterogeneous mix of cell types of diverse origins, one might not find a difference that is unique to a single-cell lineage. Again, think of the cancer model. To find the driver mutation, one must sequence the malignant cell and experimentally demonstrate a functional role of the mutation. Doing this in cancer has demonstrated multiple mutations and often different mutations within the same tumor, driven by continuing proliferation in the presence of defective DNA repair. 22 In that sense, tumor biology may be an imperfect model, as somatic mutations in brain would presumably be limited by the end of cell division. Furthermore, in the brain, we will need to go beyond brain regions to interrogate unique cell lineages implicated in the pathophysiology of the disease, such as a specific clone of parvalbumin-positive interneurons in schizophrenia, to test the hypothesis.
The technology is becoming available from the single-cell biology program. 21 The brain samples exist to look for these mutations, aided by DNA being more stable than RNA. Although transcriptional differences might indicate cortical regions of interest, it will not be sufficient to test genomic DNA in tissue samples from different brain regions alone. The use of single-cell technology or laser capture of a given lineage should focus the search. For much of the neocortex, the columnar organization constrains cell lineage, providing a rough localization of the proliferative path. But even within columns or minicolumns, there may overlapping pyramidal cell populations representing independent lineages. The migratory pathways for interneurons, possibly most important for mental illness, are complex and still being resolved. 23 And for glia, the migratory pathways in development (and the timing) may be quite different from neurons.
Which cell lineage to test is a difficult question, but one could start simply comparing several populations from the same tissue sample of a single individual and referencing those to germline DNA. With a concurrent measure of the transcriptome, the functional implications of a DNA difference should be apparent.
Somatic mutations will require brain tissue for analysis and will not be detected by germline, iPS cell or whole-brain genetics. This is not an argument for abandoning these other approaches. There will likely be many informative avenues to study the full genetic architecture and its related molecular pathophysiology of brain disorders. A search for somatic mutations is simply a different pathway that has yet to be pursued as a possible approach to pathophysiology. Given the surprises recently revealed from studies of the brain transcriptome and mindful of Haldane's maxim, the brain's genome or more accurately genomes, may prove to be even stranger than we have imagined.
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NOTE ADDED TO THE PROOF
Since the acceptance of this commentary, the first single-cell analysis of endogenous human frontal cortex neurons was published, revealing that 13-41% of neurons have at least one megabase-scale de novo CNV, that deletions
